
Photo taken from Nizar Jacques Bahlis/Twitter
Mar 15, 2024, 15:46
Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies
Nizar Jacques Bahlis, Associate Professor of Medicine at the University of Calgary, posted on X:
“SMM: Taking the narrow over the wide path. This is a plea (and not a criticism) to the myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM (Smoldering multiple myeloma) as MGUS or MM.”
Read Further.
Source: Nizar Jacques Bahlis/ X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04
Feb 22, 2025, 14:43
Feb 22, 2025, 14:10
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10